Otolith Labs develops a noninvasive wearable solution for chronic vertigo through patented technology utilizing non-invasive Vestibular Resonance Therapy (nVRT).

Otolith Labs

Bose Corporation is a privately held company specializing in audio equipment, including home audio systems, speakers, and headphones. It is also known for its automotive sound systems, which are designed to deliver high-quality audio experiences in vehicles.

Bose Corporation

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company was founded in 1981 and is headquartered in Sydney, Australia.

Cochlear Limited

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Metric
Company Name	Otolith Labs	Bose Corporation	Cochlear Limited	Frequency Therapeutics, Inc.
Symbol			COH	FREQ
MSH ID	COM:OTOLITHLABS	COM:BOSE	COM:COCHLEAR	COM:FREQUENCYTX
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Consumer Goods	Healthcare	Healthcare
Industry	Medical Devices	Consumer Electronics	Medical - Devices	Biotechnology
Country	US	US	AU	US
Stage
Employee Count		6.62K	4.80K	46
Website	otolithlabs.com	bose.com	cochlear.com	frequencytx.com
LinkedIn		bose-corporation
Founders

Metric
Market Cap	13.54B	10.94M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue			1.43B
Revenue (LTM)
Revenue (NTM)
Gross Profit			1.07B
EBITDA			383.89M
Operating Income			330.15M
Net Income			225.88M
EPS			3.44
Diluted EPS			3.44
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.75
Operating Profit Margin			0.23
EBITDA Margin			0.27
Net Profit Margin			0.16
Return on Equity			0.20
Return on Assets			0.14
Return on Capital Employed			0.25

OTOL

COM:OTOLITHLABS

Otolith Labs

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			67.35
P/B Ratio			11.58
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			10.38
EV Multiple			39.91

Metric
Days Sales Outstanding			82.48
Days Payables Outstanding			202.25
Days Inventory Outstanding			254.29
Operating Cycle			335.43
Cash Conversion Cycle			138.54
Asset Turnover			0.86

Metric
Operating Cash Flow			246.14M
Free Cash Flow			189.29M
Cash Flow to Debt			2.08
Operating Cash Flow/Sales			0.20
Free Cash Flow Yield			0.02

Metric
Cash & Equivalents			325.14M
Accounts Receivable			-33.93M
Inventory			247.91M
Goodwill			163.14M
Debt to Capitalization			0.12
Debt to Assets			0.08
Current Ratio			2.36
Quick Ratio			1.94

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.01
R&D to Revenue			0.13
SG&A to Revenue			0.11